{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:27:52Z","timestamp":1786717672748,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0973-1482.191623","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T04:14:45Z","timestamp":1475813685000},"page":"23","source":"Crossref","is-referenced-by-count":6,"title":["Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis"],"prefix":"10.4103","volume":"12","author":[{"given":"Peng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingmu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.191623-1","first-page":"49","volume-title":"Management of chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors treatment","author":"Wieczorek","year":"2016","journal-title":"Biomark Insights"},{"key":"key-10.4103\/0973-1482.191623-2","first-page":"S159","volume-title":"Management of chronic myeloid leukemia in blast crisis","author":"Sau\u00dfele","year":"2015","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0973-1482.191623-3","first-page":"1440","volume-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","author":"Thompson","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0973-1482.191623-4","first-page":"687","volume-title":"Chronic myeloid leukemia: Current perspectives","author":"Zhang","year":"2011","journal-title":"Clin Lab Med"},{"key":"key-10.4103\/0973-1482.191623-5","first-page":"2033","volume-title":"Discovery of the Philadelphia chromosome: A personal perspective","author":"Nowell","year":"2007","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0973-1482.191623-6","first-page":"553","volume-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0973-1482.191623-7","first-page":"177","volume-title":"Meta-analysis in clinical trials","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key-10.4103\/0973-1482.191623-8","first-page":"557","volume-title":"Measuring inconsistency in meta-analyses","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key-10.4103\/0973-1482.191623-9","first-page":"4497","volume-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.191623-10","first-page":"424","volume-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.191623-11","first-page":"2511","volume-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.191623-12","first-page":"1634","volume-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-a in newly diagnosed chronic myeloid leukemia","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.191623-13","first-page":"1562","volume-title":"High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients \u2013 final analysis of a randomized, multicenter, phase III trial","author":"Petzer","year":"2012","journal-title":"Haematologica"},{"key":"key-10.4103\/0973-1482.191623-14","first-page":"223","volume-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0973-1482.191623-15","first-page":"91","volume-title":"High-dose imatinib compared standard-dose in the treatment of chronic myeloid leukemia patients","author":"Guanghong","year":"2015","journal-title":"World Latest Med Inf"},{"key":"key-10.4103\/0973-1482.191623-16","first-page":"3758","volume-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the international randomized study of interferon and STI571 (IRIS)","author":"Hughes","year":"2010","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:27:15Z","timestamp":1786714035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0973-1482.191623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["191623"],"URL":"https:\/\/doi.org\/10.4103\/0973-1482.191623","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}